23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.

N French; J Nakiyingi; L M Carpenter; E Lugada; C Watera; K Moi; M Moore; D Antvelink; D Mulder; E N Janoff; J Whitworth; C F Gilks

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.

Authors

French, N
Nakiyingi, J
Carpenter, L M
Lugada, E
Watera, C
Moi, K
Moore, M
Antvelink, D
Mulder, D
Janoff, E N
Whitworth, J
Gilks, C F

Type

Published Article

Journal

The Lancet

Publisher

Elsevier BV

Publication Date

Jun 17, 2000

Volume

355

Issue

9221

Pages

2106–2111

Identifiers

PMID: 10902624

Source

Medline

Keywords

License

Unknown

Abstract

23-valent pneumococcal polysaccharide vaccination is ineffective in HIV-1-infected Ugandan adults and probably has little, or no, public health value elsewhere in sub-Saharan Africa. Increased rates of pneumococcal disease in vaccine recipients may necessitate a reappraisal of this intervention in other settings.

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. This record was last updated on 07/03/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM. The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/10902624

Report this publication

Statistics

Seen <100 times